Tag Archives: investing

Accelerate Your Fundraising with Life Science Nation’s BD Assist 

7 Jul

By Sougato Das, President and COO, LSN

Sougato-Das

Raising capital is rarely about finding more investors. It’s about finding the right investors, telling the right story, and consistently building relationships that lead to meaningful opportunities. Additionally and importantly, it is about having a dedicated resource that finds those investors, reaches out to them regularly, and secures meetings with them.

Life Science Nation’s BD Assist program was created to help early-stage life science companies do exactly that by making Life Science Nation into that dedicated resource.

BD Assist is LSN’s premier business development program, providing startups with an experienced team dedicated to advancing their fundraising and partnering efforts throughout the year. Designed for companies seeking investment, licensing opportunities, or strategic collaborations, the program combines targeted investor research, strategic messaging, personalized outreach, and ongoing business development support into one comprehensive solution.

Every engagement begins by refining the company’s investment narrative and marketing materials to ensure they clearly communicate the value of the technology, market opportunity, and growth strategy. From there, Life Science Nation identifies and prioritizes a highly targeted global audience of investors and strategic partners whose interests align with the company’s stage, therapeutic area, and business objectives.

With the strategy in place, LSN launches and manages a personalized outreach campaign on the company’s behalf, tracking every interaction through the client’s CRM platform. Outreach is continuously refined based on engagement, allowing companies to build momentum over time while maintaining visibility with investors and corporate partners actively seeking new opportunities.

Clients also benefit from regular strategy discussions, ongoing campaign optimization, and access to Life Science Nation’s extensive global investor ecosystem. For companies participating in RESI conferences, BD Assist extends that support by managing partnering activities and helping maximize high-value meeting opportunities throughout the event.

Unlike traditional consulting services that provide recommendations, BD Assist becomes an extension of your business development team. LSN handles the day-to-day execution so your leadership can remain focused on advancing the science, growing the business, and preparing for meaningful investor conversations.

Whether you are preparing for your first institutional raise, expanding into new markets, or pursuing strategic partnerships, BD Assist provides the expertise, infrastructure, and execution to help accelerate your fundraising journey.

If your goal is to spend less time searching for investors and more time building relationships with the right ones, BD Assist was built for you.

Ready to activate your global roadshow? Click here to fill out the LSN Labs company assessment report and we’ll be in touch with you soon.

Click Here to Fill Out the LSN Labs Company Assessment Report

Tags: , , , , , , , , , , , , , , , , , , , , , ,

KBIC Japan Life Science Showcase Strengthens Cross-Border Partnerships at RESI San Diego

7 Jul

By Momo Yamamoto, Senior Investor Research Analyst, LSN

The KBIC Japan Life Science Showcase brought together Japanese innovators, investors, corporate leaders, and government representatives during RESI San Diego to highlight emerging technologies and strengthen collaboration between Japan and the global life science community. As Japan’s largest biomedical cluster and title sponsor of the RESI Conference, the Kobe Biomedical Innovation Cluster (KBIC) brings together approximately 350 companies, medical institutions, and research organizations advancing healthcare innovation. The showcase featured eight Japanese startups selected for their readiness to engage with international investors and licensing partners, providing a platform to introduce their technologies to a global audience.

Each startup delivered a six-minute company presentation followed by five minutes of live Q&A in front of investor judges, giving attendees the opportunity to explore each company’s science, commercialization strategy, and market potential through direct discussions with the founders. The showcase featured an accomplished panel of judges representing Alumni Ventures, Aquillius Ventures, Bristol Myers Squibb, JLABS (Johnson & Johnson), and Mass Medical Angels. Drawing expertise across venture capital, corporate innovation, and early-stage investing, the judges engaged founders with thoughtful questions and constructive feedback, creating meaningful dialogue throughout the session.

Complementing the startup presentations, representatives from JIC Venture Growth Investments and Japan’s Ministry of Economy, Trade and Industry (METI) shared insights into Japan’s evolving venture capital landscape, government initiatives supporting innovation, and the future outlook for the country’s startup ecosystem. Their presentations provided valuable context for international investors interested in partnering with Japanese life science companies.

More than a series of company presentations, the KBIC Japan Life Science Showcase demonstrated the growing momentum behind cross-border collaboration in life sciences. By connecting Japan’s innovative startup ecosystem with U.S. and international investors, strategic partners, and industry leaders, the session reinforced a shared commitment to accelerating healthcare innovation through global partnerships. Events like these continue to strengthen the bridge between regional ecosystems, creating new opportunities for investment, licensing, and commercialization that benefit both the Japanese and international life science communities.

Tags: , , , , , , , , , , , , , , , ,

Hot Investor Mandate: Early-Stage Focused Fund Invests in Seed to Series A Rounds in Digital Health and Healthtech Companies

30 Jun

The firm is an early-stage venture capital firm headquartered in Europe and currently investing from its second fund. The firm focuses on startups with proprietary technology and strong global growth potential across deeptech, future of work, fintech, healthtech, and digital health. The firm typically invests in Seed and Series A rounds, generally leading financings while also participating as a syndicate or co-investor when appropriate. Typical investment sizes range from approximately €700K to €1.5M. While the firm invests internationally, companies with connections to the Southeastern European region are viewed favorably.

The firm focuses on healthtech and digital health companies developing software-driven healthcare solutions. The firm is agnostic across healthcare subsectors and disease areas, provided the technology is primarily software-based and demonstrates meaningful innovation, scalability, and commercial potential.

From a company and management team perspective, the firm does not impose strict requirements but values founders with deep domain expertise, strong technological differentiation, and defensible intellectual property. Companies with ties to the Southeastern European ecosystem are considered a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Private Investment Firm with Asset-Centric Approach Invests in Promising Early-Stage Therapeutics Assets

30 Jun

The firm is a private investment firm utilizing an asset-centric drug development model to advance early-stage biopharmaceutical programs. Rather than making traditional company-level investments, the firm primarily invests directly in individual therapeutic assets through flexible and innovative transaction structures. The firm can commit up to $25M or more per program, typically funding development through Phase II clinical proof-of-concept before pursuing value realization through licensing or acquisition by larger pharmaceutical companies. The firm invests globally and maintains a concentrated portfolio of high-potential therapeutic programs.

The firm focuses exclusively on biopharmaceutical assets, including small molecules, biologics, and advanced therapeutic modalities such as cell and gene therapies. The firm evaluates opportunities from approximately 12 to 18 months prior to IND through Phase I clinical development, with a preference for IND-ready, patent-protected programs addressing significant unmet medical needs and offering meaningful commercial potential. The firm is indication-agnostic and is open to a broad range of therapeutic areas where proof-of-concept can be established through early clinical studies.

From a company and management team perspective, the firm seeks founders with deep scientific and pharmacological expertise who are committed to a highly collaborative development model. The firm typically partners with lean, experienced teams and integrates each asset into a dedicated development structure while allowing founders to remain actively involved in program leadership. As a hands-on strategic partner, the firm provides extensive drug development expertise, operational resources, and industry relationships to efficiently advance programs through key value-inflection milestones.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Asia-Based VC Firm Invests in Early and Growth-Stage Opportunities in Life Sciences, Open to Cross Border Investment

30 Jun

The firm is a government-backed venture capital firm headquartered in Asia. The firm manages a large growth-stage investment fund while increasingly expanding its focus to earlier-stage innovation with global potential. Typical initial investments are approximately $5M, with the flexibility to deploy substantially larger amounts depending on the opportunity. Although the firm has historically invested primarily in domestic growth-stage companies, it is actively seeking early-stage opportunities globally.

The firm invests across therapeutics, digital therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across all disease areas. The firm generally prefers programs that have entered early clinical development and is less inclined to invest in preclinical-stage assets. Beyond therapeutics, the firm remains open to innovative healthcare technologies with strong commercial and global growth potential. From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm is open to acting as either a lead investor or co-investor and typically seeks board representation when serving as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Pharma Corporate Venture Arm Makes Strategic Investments in Therapeutics Companies, Focusing on Pre-Clinical Stage

30 Jun

The firm is the corporate venture capital arm of a global biopharmaceutical company and invests to support long-term strategic innovation alongside financial returns. The firm makes equity investments in emerging biotechnology companies, with typical initial investments ranging from approximately $1M to $6M and meaningful reserves for follow-on financings. The firm maintains a flexible investment pace and actively evaluates opportunities globally.

The firm focuses exclusively on biopharmaceutical companies developing therapeutics and therapeutic platform technologies, primarily at the preclinical stage. The firm is modality-agnostic and evaluates opportunities across small molecules, biologics, nucleic acid therapeutics, gene therapies, and cell therapies. Areas of strategic interest include immunology and autoimmune diseases, neuroscience with an emphasis on neurodegenerative disorders, and oncology. The firm does not invest in diagnostics, medical devices, or healthcare IT.

From a company and management team perspective, the firm seeks experienced leadership teams with strong domain expertise and scientific credibility. As a strategic investor, the firm typically prefers board representation and works closely with portfolio companies to support long-term development and strategic collaboration opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

RESI San Diego Innovator’s Pitch Challenge Winners Showcase the Future of Life Science Innovation

30 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) returned to RESI San Diego 2026, bringing together some of the most promising early-stage life science companies for one of the conference’s signature events. Designed to connect early-stage innovators with active investors and strategic partners, the IPC provides a platform for companies to showcase breakthrough technologies while gaining valuable exposure and feedback.

Each finalist delivered a six-minute presentation followed by a live Q&A with an investor judging panel. Throughout the conference, participants also met with investors during one-on-one partnering meetings and networking sessions, extending conversations well beyond the pitch stage.

The IPC winners are determined through a combination of investor judge evaluations and RESI Cash voting. Judges evaluate each company based on the strength of its technology, investment opportunity, presentation, and responses during Q&A, while attendees allocate RESI Cash to the companies they believe demonstrate the greatest investment potential. Together, these scores recognize companies that impressed both the judging panel and the broader RESI community.

Congratulations to the overall winners of the RESI San Diego 2026 Innovator’s Pitch Challenge: 

1st Place: Nanotrace

Nanotrace combined the best attributes of chemotherapy, nanoparticle delivery mechanisms, and the latest advancements in gene therapeutics to build a revolutionary oncology platform. Based on our team’s decades of research in these fields, and the maturation of nanomedicine, our product is a novel targeting platform which recognizes cancer cells by its very blueprint – gene expression. In part by using AI, that highly specific recognition is programmed to release a chemotherapeutic payload inside a cancer cell while leaving healthy cells unaffected. Our platform will transform how we treat not only cancer but a whole spectrum of genetic disorders. Nanotrace is founded by Dr. Will Briley, PhD Molecular Biology from Northwestern; Dr. Paul Weiss, renowned nanoscientist, distinguished UCLA professor, and a UC Presidential Chair; David Spector, an experienced founder and formerly of Sequoia Capital, Google, and MIT; and, Chief Medical Advisor, Dr. Krishna Komanduri, Department Chief & Head of Hematology & Oncology, UCSF.

2nd Place: Pinion Immunotherapeutics

Pinion Immunotherapeutics is a Maryland-based biotechnology company focused on developing novel immunotherapies for chronic viral infections and virus-driven cancers. Its proprietary AI-driven mRNA platform generates immunotherapies targeting HPV-related precancer, AML, EBV, and HSV, designed to activate CD8⁺ T cells while inducing virus-neutralizing antibodies to achieve durable immune control. Pinion operates as a lean, high-impact virtual company, deploying capital directly to science and clinical trials, not overhead. Our leadership team brings deep expertise across mRNA platform development, FDA regulatory strategy, clinical trial design, and immunology. Our programs target indications with large addressable populations, no curative standard of care, and high economic burden, where mRNA immunotherapy offers a genuine path to functional cure.

3rd Place: FELIQS

Feliqs is a clinical-stage ophthalmology company developing innovative therapies for retinal and corneal diseases with significant unmet medical needs. The company is advancing a diversified pipeline targeting conditions including retinopathy of prematurity (ROP), pterygium, and dry age-related macular degeneration (Dry AMD), addressing diseases that currently have limited or no effective treatment options. Leveraging novel mechanisms targeting oxidative stress, fibrosis, and angiogenesis, FELIQS is developing patient-friendly therapies designed to reduce dependence on invasive procedures while improving long-term visual outcomes. Through its innovative ophthalmology pipeline, FELIQS aims to preserve vision, prevent blindness, and improve quality of life for patients worldwide.

In addition to the overall winners, several companies earned the highest combined judge and RESI Cash scores within their individual pitch sessions. Congratulations to these outstanding innovators for delivering exceptional presentations and capturing investor interest throughout the competition.

3Helix Ad-Astra Allander-Biotechnologies
BOOST-Pharma Endeavor FELIQS
HEPHAISTOS Nanotrace Numiera
Pinion Rejuvenation Repair
Sebastian Wavegate

Every company that participated in the Innovator’s Pitch Challenge demonstrated the innovation, passion, and entrepreneurial spirit that continue to define the RESI community. Congratulations to all of this year’s participants.

Will Your Company Be Next?

Applications are now open for the RESI Boston Innovator’s Pitch Challenge, taking place during the expanded two-day, in-person RESI Boston conference this September during Biotech Week Boston.

The IPC is more than a pitch competition. It is an opportunity to present your company to active investors, receive expert feedback, gain additional visibility through poster presentations and partnering meetings, and compete for recognition among the global life science investment community.

Whether you’re preparing for your next financing round or looking to build strategic partnerships, the Innovator’s Pitch Challenge can help elevate your fundraising efforts.

Applications are now open. Apply today and take the stage at RESI Boston.

Apply to Pitch at RESI Boston

Tags: , , , , , , , , , , , , , , , , , , , ,

← Older Entries